Welcome to our dedicated page for BioAtla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on BioAtla stock.
BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biopharmaceutical company committed to advancing the treatment of cancer through its innovative protein therapeutic products. Headquartered in San Diego, California, with a strategic presence in Beijing, China, BioAtla leverages its proprietary Conditionally Active Biologics (CAB) technology to develop novel monoclonal and bispecific antibodies.
The core of BioAtla's work lies in the engineering of antibodies that become active under the unique conditions of the tumor microenvironment, thus improving tumor selectivity and reducing on-target toxicity. This technology aims to enhance the therapeutic index of drug candidates, ultimately providing safer and more effective cancer treatments.
BioAtla's pipeline includes several promising candidates. Mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) are in Phase 2 clinical testing, targeting AXL and ROR2 respectively. Another key asset, evalstotug (BA3071), is a CTLA-4 inhibitor designed to minimize systemic toxicity and facilitate safer combination therapies with anti-PD-1 antibodies. Furthermore, the company's first bispecific T-cell engager antibody, BA3182, is undergoing Phase 1 trials, focusing on EpCAM and engaging CD3 expressing T cells.
BioAtla has an extensive patent portfolio, with over 750 patents filed, more than 475 of which have been granted. This robust intellectual property coverage supports the company's competitive edge in the biotechnology sector.
Recent updates include the initiation of a Phase 1 clinical trial for BA3361, a next-generation CAB-Nectin4-ADC, which demonstrated superior activity in pancreatic cancer models. The company also continues to build strategic partnerships and collaborations to advance its research and commercialize its products effectively.
For further information and the latest updates, visit BioAtla's official website or contact their investor relations team.
BioAtla (BCAB) reported Q3 2024 financial results and clinical progress. Key highlights include promising data from ozuriftamab vedotin Phase 2 trial in head and neck cancer showing 9-month median overall survival, and evalstotug demonstrating tumor reduction in melanoma patients. The company received FDA guidance for potential registrational trials in 2025. Q3 net loss was $10.6M, with revenue of $11.0M from a licensing agreement. R&D expenses decreased to $16.4M from $28.4M year-over-year. Cash position of $56.5M is expected to fund operations into early 2026.
BioAtla (BCAB), a clinical-stage biotechnology company developing Conditionally Active Biologic antibody therapeutics for solid tumors, will host a conference call and webcast on November 7, 2024, at 4:30 p.m. ET to discuss its third quarter 2024 financial results and business highlights. The financial results press release will be available before the conference call on the company's website. A replay will be accessible through the Investors section.
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown Convention Center in Houston, TX.
The presentation, titled 'Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors', is scheduled for Friday, November 8, 2024, at 9:00a CDT in Exhibit Halls AB. The presentation materials will be available on the 'Publication' section of BioAtla's website after the presentation concludes.
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming oral presentation at the Society for Melanoma Research 21st International Congress (SMR) in New Orleans, LA, from October 10–13, 2024.
The presentation details are as follows:
- Title: Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity
- Presenting Author: William Boyle, Ph.D.
- Session Category: Developmental Immunotherapy
- Date & Time: Friday, October 11th, 2024 from 8:00am–10:20am CDT
The abstract will be published in the 2024 SMR Abstract book and online in the PCMR journal. Presentation materials will be available on BioAtla's website after the presentation concludes.
BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:
1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and near-term milestones
3. Potential for up to $118.5 million in additional clinical, regulatory, and commercial milestones, plus royalties on net sales
4. Context anticipates IND filing for BA3362 in mid-2026
This agreement allows BioAtla to focus on its lead clinical CAB programs while potentially advancing BA3362 under Context's leadership. The transaction aligns with Context's strategy of building a pipeline of TCE assets through strategic in-licensing or acquisition.
BioAtla (NASDAQ: BCAB) presented promising Phase 2 trial data for ozuriftamab vedotin, a conditionally active ROR2-ADC, in treating squamous cell carcinoma of the head and neck (SCCHN) at the 2024 ESMO Annual Meeting. The trial showed an overall response rate of 32% across two dosing regimens, including an ongoing complete response. The drug demonstrated meaningful antitumor activity with manageable tolerability in heavily pretreated patients.
Key highlights include:
- 77% disease control rate
- 10 responses (1 CR, 9 PRs) among 31 evaluable patients
- Well-tolerated treatment with mostly low-grade adverse events
- FDA Fast Track Designation for R/M SCCHN treatment
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona, Spain. The presentation, titled 'Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN),' will be presented on September 14, 2024. The poster (Number: 868P) will showcase BioAtla's research on Conditionally Active Biologic antibody therapeutics for solid tumor treatment. Presentation materials will be available on the company's website after the event.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024. BioAtla's management will provide a corporate update in a pre-recorded fireside chat format, which will be available on-demand starting Monday, September 9, at 7:00 a.m. ET.
BioAtla specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors. This conference participation offers an opportunity for investors and industry professionals to gain insights into BioAtla's latest developments and strategic direction in the field of oncology therapeutics.
BioAtla (NASDAQ: BCAB) reported Q2 2024 financial results and clinical progress. Key highlights include:
1. Ozuriftamab vedotin granted Fast Track Designation by FDA for head and neck cancer; FDA meeting anticipated in 2H 2024.
2. Evalstotug showed low incidence of immune-related adverse events; Phase 2 combination study with pembrolizumab on track for initial data in 2H 2024.
3. Mecbotamab vedotin Phase 2 trial in NSCLC showed improved overall survival in patients with KRAS mutations.
4. Cash balance projected to fund operations through Q3 2025.
5. Q2 2024 financial results: R&D expenses $16.2M (down from $31.0M in Q2 2023), G&A expenses $5.8M, net loss $21.1M, cash and equivalents $61.7M as of June 30, 2024.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced its upcoming second quarter 2024 financial results and business highlights conference call. The event is scheduled for Thursday, August 8, 2024, at 4:30 p.m. ET.
Investors and interested parties can access the webcast through the provided link or join via phone using the dial-in numbers. The financial results press release will be available on the company's website prior to the call. A replay of the conference call will also be accessible through the Investors section of BioAtla's website.
FAQ
What is the current stock price of BioAtla (BCAB)?
What is the market cap of BioAtla (BCAB)?
What is BioAtla, Inc. known for?
Where are BioAtla's main operations located?
What are BioAtla's leading drug candidates?
What is CAB technology?
How extensive is BioAtla's patent portfolio?
What recent developments has BioAtla announced?
Who can I contact for more information about BioAtla?
What types of cancers are BioAtla's treatments targeting?
What are the benefits of BioAtla's CAB technology?
Where can I find BioAtla's latest news and updates?
